TOXINS 2022 Conference Program

Wednesday, July 27, 2022
Wednesday, July 27, 2022
8:00 am – 5:00 pm Poster Hall Setup
9:00 am – 8:30 pm Registration Opens
6:00 pm – 8:00 pm Welcome Reception
Poster Hall Open

Thursday, July 28, 2022
7:30 am – 6:30 pm Registration/Information
7:30 am – 8:30 am Breakfast
Poster Hall Open
8:30 am – 12:00 noon Plenary Session
8:30 am – 8:45 am Opening Remarks
Chair: Cynthia Comella, MD (USA)
8:45 am – 9:30 am Engineering Bacterial Toxins Into Therapeutics
Keynote Speaker: Min Dong, PhD (USA)
9:30 am – 10:00 am Focus on BoNT Engineering
(Phage–Assisted Evolution of Botulinum Neurotoxin Proteases With Reprogrammed Specificity)
Travis Blum, PhD (USA)
10:00 am – 10:30 am Basis of Movement Control and Why Botulinum Toxin Should Influence It
Aparna Wagle Shukla, MD (USA)
10:30 am – 11:00 am Break
Poster Hall Open
11:00 am – 12:00 noon Botulinum Toxin in the COVID Era: Issues and Challenges
Moderator: Barbara Karp, MD (USA)
Chris Boulias, MD, PhD (Canada)
Francisco Cardoso, MD (Brazil)
David Simpson, MD (USA)
12:00 noon – 2:00 pm Lunch
Poster Hall Open

Time Basic Science Track Time Clinical Track 1A Time Clinical Track 2A Time Clinical Track 3A Time Clinical Track 4A
2:00 pm – 3:35 pm History, Genetics, and Evolution
Chair: Ornella Rossetto, PhD (Italy)
2:00 pm – 3:35 pm Adult Spasticity I
Chair: Alberto Esquenazi, MD (USA)
2:00 pm – 3:35 pm Cervical Dystonia
Chair: Alberto Albanese, MD (Italy)
2:00 pm – 3:35 pm Aesthetic Medicine and Dermatology
Chair: Steven Yoelin, MD (USA)
2:00 pm – 3:35 pm Genitourinary and Gastrointestinal Botulinum
Toxin Applications
Chair: Roger Dmochowski, MD (USA)
2:00 pm – 2:20 pm Geographical Distribution of
Clostridium botulinum Phyla
Carolina Luquez, PhD (USA)
2:00 pm – 2:25 pm What's New? BoNT Clinical Trial Update: Adult Spasticity
Gerard Francisco, MD (USA)
2:00 pm – 2:25 pm What's New? BoNT Clinical Trial Update: Cervical Dystonia
Cynthia Comella, MD (USA)
2:00 pm – 2:40 pm Essential Anatomy and InjectionTechnique: Neuromodulators for Aesthetic Use in the Upper, Mid and Lower Face
Wendy Lee, MD, MS (USA)
Steven Yoelin, MD (USA)
2:00 pm – 2:30 pm Update on the Management of Overactive Bladder
Linda Cardozo, MD (UK)
2:20 pm – 2:40 pm Chromosomally Integrated Plasmids in G1 C. botulinum
Kristin Schill, PhD (USA)
2:25 pm – 2:50 pm Gait Pattern Recognition and Muscle Selection for BoNT Injections
Alberto Esquenazi, MD (USA)
2:25 pm – 2:50 pm Anatomy and Ultrasound-Guided Injection of Deep Neck Muscles
for Anterocollis
Katharine Alter, MD (USA)
2:40 pm – 3:10 pm Clinical Implications of the Long-Term Use of Neuromodulators for Aesthetic Indications
Michael Kane, MD (USA)
2:30 pm – 3:00 pm Applications of Botulinum Toxin:
The Female Pelvic Floor
Barbara Karp, MD (USA)
2:40 pm – 3:35 pm Round Table: Bacterial Nomenclature in the Genomic Era—Considerations of Nomenclature Changes of Clostridium botulinum

1. Bacterial Nomenclature Rules and Implications of Classification Changes of Bacteria of Medical Importance
Marc Allard, PhD (USA)

2. Botulinum Neurotoxins Producing Bacteria in the Genomic Era
Theresa J. Smith, MS (USA)

3. Implications of Re-classification of
C. botulinum From the Public Health Perspective
Carolina Luquez, PhD (USA)
2:50 pm – 3:10 pm What Are We Missing? It’s More Than Injections
Laura Wiggs, PT, NCS, CBIS (USA)
2:50 pm – 3:15 pm Functional or Psychogenic Dystonia: Should We Inject BoNT?
Alberto Albanese, MD (Italy)
3:10 pm - 3:25 pm OnabotulinumtoxinA for Treatment of Masseter Muscle Prominence and Masseter Muscle Hypertrophy:
Results From Phase 2 Studies
Jason Rivers, MD (Canada)
3:00 pm - 3:30 pm The Urinary Tract and Neurotoxin
Roger Dmochowski, MD (USA)
3:10 pm - 3:35 pm What Are the Early Risk Factors for Disabling Spasticity—Does BoNT Treatment Reduce the Risk Effectively?
Anthony Ward, MBE, BSc, MD, FRCP (UK)
3:15 pm - 3:30 pm A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia
Cynthia Comella, MD (USA)
3:25 pm - 3:35 pm Subject Satisfaction With AbobotulinumtoxinA for
Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study
Amir Moradi, MD (USA)
3:35 pm – 3:55 pm Break
Poster Hall Open
3:35 pm – 3:55 pm Break
Poster Hall Open
3:35 pm – 3:55 pm Break
Poster Hall Open
3:35 pm – 3:55 pm Break
Poster Hall Open
3:35 pm – 3:55 pm Break
Poster Hall Open
Time Basic Science Track Time Clinical Track 1B Time Clinical Track 2B Time Clinical Track 3B Time Clinical Track 4B Time Injection Demonstration Workshop
3:55 pm – 5:30 pm Toxin Engineering and Pharmacokinetics
Chair: Andreas Rummel, PhD (Germany)
Co-chair: Michel Popoff, PhD (France)
3:55 pm – 5:30 pm Oromandibular Dystonia, Spasmodic Dysphonia, Blepharospasm, and Meige Syndrome
Chair: Andrew Blitzer, MD (USA)
3:55 pm – 5:30 pm Practical Considerations and Selected Abstracts
Chair: Chris Boulias, MD, PhD (Canada)
3:55 pm – 5:30 pm Selected Topics I
Chair: Francisco Cardoso, MD (Brazil)
3:55 pm – 5:30 pm Pediatric Spasticity
Chair: Katharine Alter, MD (USA)
3:55 pm – 5:30 pm Aesthetic Medicine and Dermatology: Round Robin Injection Workshop
Chair: Deirdre Hooper, MD (USA)
3:55 pm – 4:15 pm Botulinum Neurotoxin Trafficking Within Motor Neurons
Patrick M. McNutt, PhD (USA)
3:55 pm – 4:15 pm Oromandibular Dystonia:
A Clinical Examination of 2,020 Cases
H. A. Jinnah, MD (USA)
3:55 pm – 4:25 pm Clinical Aspects Associated With BoNT Properties: Does Altering the Onset of Action and Increasing Duration of Action Really Matter in Clinical Practice?
Sarah Pirio Richardson, MD (USA)
3:55 pm – 4:25 pm Botulinum Toxin in Parkinsonian Disorders
Robert Chen, MD (Canada)
3:55 pm – 4:35 pm How do we Optimize Outcomes in Pediatric Patients? BoNT Selection, Guidance Methods, Sedation vs No Sedation
Katharine Alter, MD (USA)
3:55 pm – 5:30 pm Round Robin Injection Workshop
Julie Bass-Kaplan, FNP-BC, MSN, CANS (USA)
Deirdre Hooper, MD (USA)
Wendy Lee, MD, MS (USA)
Haley Wood, WHNP, MSN, CANS (USA)
Glenn Vallecillos, MD (USA)
Steve Yoelin, MD (USA)
4:15 pm – 4:35 pm Engineering BoNTs as Vehicles for Drug Delivery/Neuronal Delivery Vehicles Using Antibodies for BoNT Intoxication
Konstantin Ichtchenko, PhD (USA)
4:15 pm – 4:35 pm What's New? BoNT Clinical Trial Update: Oromandibular Dystonia
Nikita Kohli, MD (USA)
4:25 pm – 4:55 pm Dosing Intervals With BoNT:
Managing Multiple Indications and Boosters
David Simpson, MD (USA)
4:25 pm – 4:55 pm Use of Kinematic Analysis for Individualized Botulinum Toxin Treatment
Mandor Jog, MD (Canada)
4:35 pm – 4:45 pm Immunostaining Procedure for Ganglioside Expression Evaluation in Human Neurons
Sylvain Roqueviere, PhD (France)
4:35 pm – 5:05 pm To Treat or Not to Treat the Pediatric Patient With BoNT: Are There Long-Term Consequences?
Mark Gormley, MD (USA)
4:45 pm – 4:55 pm Cell-Penetrating Peptides:
Are They Useful Excipients in Botulinum Toxin Formulations?
James Austerberry, PhD (UK)
4:35 pm – 4:55 pm Spasmodic Dysphonia
Andrew Blitzer, MD (USA)
4:55 pm – 5:05 pm Resolution of Two Steps in Botulinum Neurotoxin Serotype A1 Light Chain Localization to the Intracellular Plasma Membrane
Alex Gardner, BS (USA)
4:55 pm – 5:20 pm How to Adjust Expectations and Manage a Newly-Diagnosed Blepharospasm and
Meige Syndrome Patient
Barbara Karp, MD (USA)
4:55 pm - 5:10 pm IncobotulinumtoxinA for Refractory Neuropathic Pain Following Breast Cancer Surgery
Eric J. Viel MD, PhD (France)
4:55 pm – 5:25 pm Effects of Toxin on Non-Motor Symptoms in Dystonia
H. A. Jinnah, MD (USA)
5:05 pm – 5:25 pm Spasticity-Related Pain in Children/Adolescents With
Cerebral Palsy
Florian Heinen, MD (Germany)
5:10 pm - 5:20 pm Current Perspectives on the Management of Cervical Dystonia Among Global Clinicians
Stephanie Standal, MD (USA)
5:05 pm – 5:15 pm Analgesic Activity of AbobotulinumtoxinA in Postoperative Pain Models in the Pig Is Driven by the Route of Administration:
New Highlights on the Mechanism of Action
Stephane Lezmi, PhD (France)
5:20 pm - 5:30 pm Comparison of Ultrasound and Electrical Stimulation Guidance for Botulinum Neurotoxin Injections:
A Randomized Cross-Over Study
David Simpson, MD (USA)

Friday, July 29, 2022
8:00 am – 6:30 pm Registration/Information
7:30 am – 8:30 am Breakfast
Poster Hall Open
8:30 am – 12:00 noon Plenary Session
8:30 am – 8:40 am Welcome Back
Chair: Giampietro Schiavo, PhD (UK)
8:40 am – 9:05 am BoNT as a Treatment Option for Age-Related Macular Degeneration
Gary Borodic, MD (USA)
9:05 am – 9:35 am Antipruritic Effect of BoNTs
Parisa Gazerani, PharmD, PhD (Denmark)
9:35 am – 10:05 am BoNT in the Management of Neuropathic Pain
Nadine Attal, MD, PhD (France)
10:05 am – 10:30 am The Emerging Role of Botulinum Toxin
in Cardiology
Jonathan S. Steinberg, MD (USA)
10:30 am – 11:00 am Break
Poster Hall Open
11:00 am – 12:00 noon Depression Roundtable: Is There a Role for BoNT?
Moderator: Alberto Albanese, MD (Italy)
Nicholas A. Coles, PhD (USA)
Eric Finzi, MD, PhD (USA)
Lori Kels, MD, MPH (USA)
Giampietro Schiavo, PhD (UK)
12:00 noon – 2:00 pm Lunch
Poster Hall Open

Time Basic Science Track Time Injection Workshop 1A Time Clinical Track 2A Time Clinical Track 3A Time Clinical Track 4A
2:00 pm – 3:20 pm BoNT Detection and Countermeasures
Chair: Patrick McNutt, PhD (USA)
2:00 pm – 3:35 pm Therapeutic Use of BoNT Injection Demonstration Workshop
Chair: Cynthia Comella, MD (USA)
2:00 pm – 3:35 pm Headache and Pain
Chair: Cristina Tassorelli, MD (Italy)
2:00 pm – 3:35 pm Aesthetic Medicine
and Dermatology
Chair: Nowell Solish, MD (Canada)
2:00 pm – 3:35 pm Adult Spasticity II
Chair: Anthony Ward, MBE, BSc, MD, FRCP (UK)
2:00 pm – 2:20 pm Detection of Select Agent Toxins in Support of Public Health Activities
Suzy Kalb, PhD (USA)
2:00 pm – 2:45 pm Cervical Dystonia and Oromandibular Dystonia
Sarah Perez, MD (USA)
2:00 pm – 2:25 pm BoNT for Suppression of Chronic Migraine: What Have We Learned
in 10+ Years?
Peter McAllister, MD (USA)
2:00 pm – 2:30 pm Update on Hyperhidrosis
Dee Anna Glaser, MD (USA)
2:00 pm – 2:35 pm Balancing Dosing in Patients Who Need More Than You Can Give
Cindy Ivanhoe, MD (USA)
2:20 pm – 2:40 pm Monoclonal Antibody Combinations for the Prevention and Treatment
of Botulism
Jim Marks, PhD (USA)
2:25 pm – 2:45 pm Potential Use of BoNT in Treating Other Primary Headache Disorders
and Facial Pain
Cristina Tassorelli, MD (Italy)
2:30 pm – 3:05 pm Micro Toxin Technique: What, Why,
and Where?
Woffles Wu, MBBS, FRCS, FAMS (Singapore)
2:35 pm – 3:00 pm Early vs Late BoNT Management of Post-Stroke Spastic Movement Disorder
Jörg Wissel, MD (Germany)
2:40 pm – 3:00 pm Fabs From Purified HumAbs Open to the Intrathecal Therapy of Tetanus
Marco Pirazzini, PhD (Italy)
2:45 pm – 3:35 pm Pediatric Spasticity
Ann Tilton, MD (USA)
2:45 pm – 3:05 pm BoNT, mAbs, and Gepants: Elegant Synergism or Expensive Redundancy?
Peter McAllister, MD (USA)
3:00 pm – 3:10 pm Novel, Genetically Engineered SNAP-25 Reporter Constructs for BoNT-A and BoNT-E Toxin Activity Measurement
3:05 pm – 3:15 pm Real-World Safety and Efficacy of 156-195 U OnabotulinumtoxinA in Participants With Chronic Migraine: Results From the REPOSE Study
Fayyaz Ahmed, MD (UK)
3:05 pm – 3:15 pm Subject Satisfaction With Two Treatments Per Year (Every Six Months) of AbobotulinumtoxinA Is High Among Both Previously Treated and Toxin-naïve Cohorts
Sarah Coquis-Knezek, PhD (USA)
3:00 pm – 3:25 pm Guided Self-Rehabilitation Combined With BoNT in Adults With
Spastic Paresis
Jean-Michel Gracies, MD (France)
3:10 pm – 3:20 pm Screening and Development of 9-Hydroxy-4H-Pyrido[1,2-a]Pyrimidin-4-One–Based Bifunctional Inhibitors of BoNT-A/LC
Ealin Patel, PhD (USA)
3:15 pm – 3:25 pm Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
Jennifer W. McVige, MD, MA, FASN (USA)
3:15 pm - 3:35 pm The Air Toxin Technique: Introduction and Analysis of Effect Using a Photo Imaging System
Wendy Lee, MD, MS (USA)

3:25 pm – 3:35 pm Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine:
A Pooled PREEMPT Analysis
Katherine Sommer, MD (USA)
3:25 pm - 3:35 pm The Impact of Isokinetic Lower Limb Muscle Strengthening Associated With Focal Spasticity Treatment on the Endurance, Strength, and Quality of Life of Multiple Sclerosis Patients
Hadjira Aboura, MD (Algeria)
3:35 pm - 3:55 pm Break
Poster Hall Open
3:35 pm - 3:55 pm Break
Poster Hall Open
3:35 pm - 3:55 pm Break
Poster Hall Open
3:35 pm - 3:55 pm Break
Poster Hall Open
3:35 pm - 3:55 pm Break
Poster Hall Open
Time Basic Science Track Time Injection Demonstration Workshop 1B Time Clinical Track 2B Time Clinical Track 3B Time Clinical Track 4B
3:55 pm – 5:25 pm Structural and Functional Aspects of BoNTs
Chair: Suzy Kalb, PhD (USA)
Co-Chair: Sabine Pellett, PhD (USA)
3:55 pm – 5:25 pm Therapeutic Use of BoNT Injection Demonstration Workshop
Chair: Anthony Ward, MD (UK)
3:55 pm – 5:30 pm Selected Topics II
Chair: Robert Chen, MD (Canada)
3:55 pm – 5:30 pm Aesthetic Medicine and Dermatology
3:55 pm – 5:30 pm Sialorrhea, Tics, Tremor, and Focal Limb Dystonia
Chair: David Simpson, MD (USA)
3:55 pm – 4:15 pm Are Non-Clostridial Homologs Botulinum Neurotoxins?
Travis Wentz, PhD (USA)
3:55 pm – 5:30 pm Adult Spasticity
Andrea Toomer, MD (USA)
3:55 pm – 4:20 pm Changes in Cortical Excitability and Plasticity After Botulinum Toxin Injection
Robert Chen, MD (Canada)
3:55 pm – 4:30 pm The Use of Neuromodulators
for Facial Shaping
Woffles Wu, MBBS, FRCS, FAMS (Singapore)
3:55 pm – 4:20 pm BoNT Clinical Trial Update: Sialorrhea
Mark Lew, MD (USA)
4:15 pm – 4:35 pm Recognition of the Protein Receptor SV2 by BoNTs
Andreas Rummel, PhD (Germany)
4:20 pm – 4:45 pm Parkinsonism: Is There a Place for BoNT Management of Posture, Rigor, Tremor, and Mobility?
Charenya Anandan, MD (USA)
4:30 pm – 5:10 pm Neuromodulators From Around the World: What’s Here and What’s to Come
Nowell Solish, MD (Canada)
4:20 pm – 4:50 pm Laryngeal Tremor, Myoclonus, and Tics:
Is There a Role for BoNT?
Andrew Blitzer, MD (USA)
4:35 pm – 4:55 pm Structure and Activity of Botulinum Neurotoxin X
Paul Stenmark, PhD (Sweden)
4:45 pm – 5:10 pm Clinical Profile of BoNT Response/Immunogenicity
Philipp Albrecht, MD (Germany)
4:50 pm – 5:15 pm Focal Limb Dystonia and Tremor:
A Look at the BoNT Data
Codrin Lungu, MD (USA)
4:55 pm – 5:15 pm Early Interactions Between Tetanus Toxin and Neuronal Cells
Joseph Barbieri, PhD (USA)
5:10 pm - 5:20 pm Applicability of Botulinum Toxin in Treatment of Holmes Tremor, Our Cases and Detailed Review of Current Literature
Eshita Shah, MD (USA)
5:10 pm – 5:30 pm Two Selected Abstracts
5:15 pm – 5:30 pm Musician’s Focal Limb Dystonia:
Results of a Placebo-Controlled Study
David Simpson, MD (USA)
5:15 pm – 5:25 pm Botulinum Toxin Type A Duration Enhancement by Mu-Conotoxin CnIIIC
Mickaël Machicoane, PhD (Switzerland)
5:20 pm - 5:30 pm OnabotulinumtoxinA, Nerve Stimulation Devices, Mirabegron, and Anticholinergics Versus Best Supportive Care For Overactive Bladder:
An Updated US Cost–Effectiveness Analysis
Christopher Chermansky, MD (USA)
5:25 pm – 5:35 pm Selected Abstract

Saturday, July 30, 2022
7:30 am – 12:00 noon Information
8:00 am – 9:00 am Breakfast
Poster Hall Open
9:00 am – 11:30 am Plenary Session
9:00 am – 9:45 am Questions About BoNT You Were Afraid to Ask
Moderator: David Simpson, MD (USA)
Cindy Ivanhoe, MD (USA)
Andreas Rummel, PhD (Germany)
Giampietro Schiavo, PhD (UK)
Nowell Solish, MD (Canada)
9:45 am – 10:15 am A Look at the Future—New BoNTs and Delivery Systems in Development:
A View From the Bench
Sabine Pellett, PhD (USA)
10:15 am – 10:45 am A Look at the Future—New BoNTs and Delivery Systems in Development:
What It Could Mean in the Clinic
Ryuji Kaji, MD (Japan)
10:45 am – 11:05 am Best Clinical Abstract
11:05 am – 11:25 am Best Basic Science Abstract
11:25 am – 11:30 am Closing Remarks
David Simpson, MD (USA)